Clene Inc. (NASDAQ: CLNN) presented positive results from the combined REPAIR-MS trial at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, demonstrating that CNM-Au8 significantly improved brain NAD+/NADH ratios, a key marker of energetic capacity, across relapsing and non-active progressive multiple sclerosis (MS) patients. The findings highlight the potential of CNM-Au8 to address bioenergetic failure in MS, a mechanism that may slow disease progression.
The study showed that treatment with CNM-Au8 produced significant changes in brain NAD+ and NADH fractions, with correlations between baseline brain energy metabolism and disability, cognition, and motor function. CNM-Au8 was safe and well tolerated, reinforcing its potential as a first-in-class therapy targeting mitochondrial health. According to the press release, the full details are available at https://ibn.fm/uuEAj.
Clene Inc., based in Salt Lake City, Utah, is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8 is an investigational therapy that improves central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress. For more information, visit www.clene.com.
The REPAIR-MS results are significant because they provide evidence that CNM-Au8 can improve brain energy metabolism in MS patients, addressing a key underlying factor in disease progression. By enhancing NAD+/NADH ratios, the therapy may help restore cellular energy balance, potentially slowing disability accumulation and cognitive decline. The safety profile observed in the trial further supports its continued development.
These findings come at a critical time for MS research, as current treatments primarily target inflammation but do not address the neurodegenerative aspects of the disease. CNM-Au8’s mechanism of action offers a novel approach that could complement existing therapies. Clene plans to advance CNM-Au8 into later-stage trials to confirm its efficacy in slowing disease progression. Investors and researchers can stay updated on CLNN developments via the company’s newsroom at https://ibn.fm/CLNN.
